Core Viewpoint - Weisheng Pharmaceutical-B (02561) experienced a significant increase of over 4% in stock price, reaching HKD 34.98 with a trading volume of HKD 966,400, following strategic partnerships announced during the 8th China International Import Expo [1] Group 1: Strategic Partnerships - Weisheng Pharmaceutical entered into a strategic cooperation for dual-chamber freeze-dried formulation technology with Dongfulong (300171), a leading domestic pharmaceutical equipment company [1] - The company also signed an industrial collaboration agreement with the Lingang New Area Administrative Committee and Lingang Group's trade platform, further implementing its strategy of "Global Innovation, China Acceleration" [1] Group 2: Product Showcase - This year marks Weisheng Pharmaceutical's debut as an exhibitor at the 8th China International Import Expo, showcasing two globally innovative drugs [1] - Among the showcased products, Parathyroid hormone replacement therapy is the world's first and only drug for treating adult chronic hypoparathyroidism (HP) [1] - The company also presented Longpei growth hormone, which aims to become a "potential best-in-class" drug [1]
维昇药业-B尾盘涨超4% 公司在进博会达成多项合作 携两款全球创新药物登场亮相